Deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression through inhibiting Hedgehog signaling and PDL1 expression

Author:

Xie Peiyi1ORCID,Chen Sisi2ORCID,Zhou Binghai3,Wei Huang2,Li Qing2,Ye Yu2,Kuang Xiuqing2,Huang Huabin2,Wang Wei2

Affiliation:

1. Liver cancer institute

2. Second Affiliated Hospital of Nanchang University

3. Hepato-Biliary-Pancreatic Surgery Division

Abstract

Abstract Hepatocellular carcinoma (HCC) is one of the deadliest malignancies in the world. Research into the key genes that maintain the malignant behavior of cancer cells is crucial for the treatment of HCC. Here, we identify ubiquitin‐specific peptidase 44 (USP44), a member of deubiquitinase family, as a novel regulator of HCC progression. The tumor suppressive function of USP44 was evaluated in a series of in vitro and in vivo experiments including using USP44 flox/flox mice and orthotopic xenograft models.Through Quantitative Proteomics examination, we demonstrated that USP44 inhibits HCC PDL1 expression through downregulating Hedgehog (Hh) signaling pathway. Mechanistically, we found USP44 directly interacts with Itch, an E3 ligase involved in Hh signaling, and promotes the deubiquitination and stabilization of Itch.These events result in the proteasomal degradationof Gli1 and subsequent inactivation of Hh signaling, which ultimately suppresses the PDL1 expression and progression of HCC. Furthermore, HCC tissue microarray was analyzed by immunohistochemistry to evaluate the pathological relevance of the USP44/Itch/Gli1/PDL1 axis. At last, Gli1 inhibitor GANT61 was found to act in synergy with anti-PDL1 therapy. Overall, USP44 can act as a suppressive gene in HCC by modulating Hh signaling and co-inhibition of Gli1 and PDL1 might be an effective novel combination strategy for treating HCC patients.

Publisher

Research Square Platform LLC

Reference38 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3